Business Context and Reporting Period
Company: NOVAVAX INC
Filing Type: Form 8-K (Current Report)
Date of Report: July 19, 2004
Reporting Period: Event date of July 19, 2004
Key Financial Metrics
Financing Activity: The company closed a financing transaction totaling $40 million.
Other Metrics: The filing text does not provide clear values for revenue, profit, cash flow, margins, debt, or liquidity.
Material Changes
- Financing Closure: On July 19, 2004, Novavax, Inc. closed its previously announced $40 million in financings.
- Strategic Transaction: The company simultaneously closed a transaction with King Pharmaceuticals, Inc.
Guidance, Outlook, and Risks
The filing text does not provide specific guidance, outlook, management commentary, risks, contingencies, or unusual items beyond the announcement of the closed transactions.
Investor Verification Checklist
- Verify the specific terms and structure of the $40 million financing.
- Confirm the details and strategic implications of the transaction with King Pharmaceuticals, Inc.
- Review subsequent filings for the impact of this capital raise on the company's cash position and operational runway.